
Aired: Wed, Oct 28th 2026, 5:00 PM
The rapid growth of RNA therapeutics, gene editing, and other nucleic acid-based medicines is placing increasing pressure on development and manufacturing supply chains. These challenges can affect timelines, scalability, product quality, and ultimately the ability to deliver therapies to patients. An integrated approach can help reduce these risks while improving operational efficiency and manufacturing readiness.
For developers evaluating partners and manufacturing strategies, integration is about more than housing multiple capabilities under one roof. The true value lies in connecting expertise, technologies, services, and data across the development journey to build manufacturing strategies that are robust, scalable, and designed to support patient safety from the outset.
In this "Before You Buy" discussion, a roundtable of experts at Sartorius will explore the critical questions developers should ask when selecting partners and defining manufacturing strategies for pDNA and RNA programs. Attendees will gain practical insights into the technical, operational, quality, and supply chain considerations that can influence long-term program success and help them make more informed decisions before committing to a development or manufacturing path.
Key learning objectives:
Speaker
Mathieu Rocaboy, New Technology Manager at Sartorius
Klemen Božič, Scientist at Sartorius
Tinkara Božič, Product Specialist at Sartorius
Host
Damon Anderson, Technology Editor at LabX

Create an account now for exclusive benefits, personalized recommendations, and seamless order tracking. Elevate your lab experience today!